Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia

British Journal of Clinical Pharmacology

Volumn 46, Issue 5, 1998, Pages 473-478

  Otto, C ^a   Parhofer, K G ^a   Ritter, M M ^a   Richter, W O ^a   Schwandt, P ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Fibrinogen; Haemorheology; Hyperlipidaemia; Lipoproteins; Mixed hyperlipoproteinaemia; Red cell aggregation

Indexed keywords

ACIPIMOX; APOLIPOPROTEIN B; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; ERYTHROCYTE AGGREGATION; ERYTHROCYTE FILTERABILITY; FEMALE; HEADACHE; HEMATOCRIT; HOT FLUSH; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; NAUSEA; PLASMA VISCOSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ANTILIPEMIC AGENTS; BLOOD VISCOSITY; CELL AGGREGATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEMORHEOLOGY; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; PYRAZINES;

EID: 0031787035     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00816.x     Document Type: Article

References (37)

1. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
2. Meade TW, Mellows S, Brozovic M, Miller GJ. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537.
3. Balleisen L, Schulte H, Assmann G, Epping PH, van de Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987; ii: 461-466.
4. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and cardiovascular disease. The Framingham Study. J Am Med Ass 1987; 258: 1183-1186.
5. Yarnell JW, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991; 83: 836-844.
6. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris Study Group. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
7. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995; 15: 1263-1268.
8. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U, for the Bezafibrate Infarction Prevention (BIP) Study Group. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arterioscler Thromb Vasc Biol 1996; 16: 351-356.
9. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
10. O'Kane MJ, Trinick TR, Tynan MB, Trimble ER, Nicholls DP. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. Br J Clin Pharmacol 1992; 33: 451-453.
11. Tornvall P, Walldius G. A comparison between nicotinic acid and acipimox in hypertriglycderidemia - effects on serum lipids, lipoproteins, glucose tolerance and tolerability. J Intern Med 1991; 230: 415-421.
12. Montefusco S, Iannaci G, Gnasso A, Cortese C, Lamenza F, Postiglione A. Blood and plasma viscosity after acipimox treatment in hypertriglyceridemic patients. Int J Clin Pharmacol Ther Toxicol 1988; 26: 492-494.
13. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983; 24: 147-155.
14. Ernst E, Monshausen C, Matrai A. Blood viscosity - A comparative study on three rotational instruments. Biorheology 1985; 22: 471-475.
15. Schmid-Schönbein H, Volger E, Teitel P, Kiesewetter U, Dauer U, Heilman L. New haemorheological techniques for the routine laboratory. Recent Adv Cardiovasc Dis 1981; 2: 27S-39S.
16. Dormandy J, Flute P, Matrai A, et al. The new St. George's blood filtrometer. Clin Hemorheol 1985; 5: 975-983.
17. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-246.
18. Utermann G, Hess J, Steinmetz A. Polymorphism of apolipoprotein E and occurence of dysbetalipoproteinemia in man. Nature 1977; 269: 604-607.
19. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978; 19: 65-76.
20. Ritter MM, Geiss HC, Richter WO, Schwandt P. Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia and hypertriglyceridemia. Metabolism 1994; 43: 572-578.
21. Berge KG, Achor RWP, Christensen NA, Mason HL, Barker NW. Hypercholesterolemia and nicotinic acid. A long-term study. Am J Med 1961; 31: 24-36.
22. Scott JT. Drug-induced gout. Baillieres Clin Rheumatol 1991; 5: 39-60.
23. Taskinen MR, Nikkilä EA. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia. Atherosclerosis 1988; 69: 249-255.
24. Crepaldi G, Avogaro P, Descovich GC, et al. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. Atherosclerosis 1988; 70: 115-121.
25. Stuyt PM, Stalenhoef AF, Demacker PN, vant't Laar A. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia. Atherosclerosis 1985; 55: 51-62.
26. Ball MJ, Vella M, Rechlass JPD, et al. Acipimox in the treatment of patients with hyperlipidemia: a double blind trial. Eur J Clin Pharmacol 1986; 31: 201-204.
27. Griffin BA, Caslake MJ, Gaw A, Yip B, Packard CJ, Shepherd J. Effects of cholestyramine and acipimox on subfractions of plasma low-density lipoprotein. Studies in normolipidaemic and hypercholesterolaemic subjects. Eur J Clin Invest 1992; 22: 383-390.
28. Franceschini G, Bernini F, Michelagnoli S, et al. Increased affinity of LDL for their receptors after acipimox treatment in hypertriglycendemia. Eur J Clin Pharmacol 1991; 40 (Suppl. 1): S45-S48.
29. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993; 101: 61-68.
30. König W, Sund M, Ernst H, Mraz W, Hombach V, Keil U. Association between rheology and components of lipoproteins in human blood. Results from the MONICA Project. Circulation 1992; 85: 2197-2204.
31. Halle M, Berg A, Keul J, Baumstark MW. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Throm Vasc Biol 1996; 16: 144-148.
32. Razavian SM, Atger V, Giral P, et al. The PCVMETRA Group. Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men. Arterioscler Thromb Vasc Biol 1994; 14: 361-366.
33. Ruhenstroth-Bauer G, Mössmer G, Ottl J, Koenig-Erich S, Heinemann G. Highly significant negative correlations between erythrocyte aggregation value and serum concentrations of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease. Eur J Clin Invest 1987; 17: 275-279.
34. Otto C, Pschierer V, Sönnichsen AC, Schwandt P, Richter WO. Postprandial hemorheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia. Metabolism 1997; 46: 1299-1304.
35. Otto C, Donner MG, Schwandt P, Richter WO. Seasonal variations of hemorheological and lipid parameters in middle-aged healthy subjects. Clin Chim Acta 1996; 256: 87-94.
36. Neumann FJ, Kauts HA, Hoberg E, et al. Increased plasma viscosity and erythrocyte aggregation: indicators of an unfavourable clinical outcome in patients with unstable angina pectoris. Br Heart J 1991; 66: 425-430.
37. Resch KL, Ernst E, Matrai A, Buhl M, Schlosser P. Can rheologic variables be of prognostic relevance in atherosclerotic diseases? Angiology 1991; 42: 963-970.